INFLARX N.V. news, videos and press releases
For more news please use our advanced search feature.
INFLARX N.V. - More news...
INFLARX N.V. - More news...
- InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones
- InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
- InflaRx to Showcase Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting
- InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences
- InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance
- InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
- InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants
- InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference
- InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)
- InflaRx Announces Participation in January Events in San Francisco
- InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904
- InflaRx Receives Positive CHMP Opinion for GOHIBIC® (Vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome
- InflaRx Reports Third Quarter 2024 Financial Results and Provides Business Update
- InflaRx to Report Third Quarter 2024 Financial Results on November 8 and to Participate in Guggenheim Inaugural Healthcare Innovation Conference
- InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress
- InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
- InflaRx Announces Participation in September Investor Events
- InflaRx Reports Second Quarter 2024 Financial Results and Provides Business Update
- InflaRx to Report Second Quarter 2024 Results on August 8, 2024
- InflaRx to Present New Preclinical Data on INF904 at the 19th European Meeting on Complement in Human Diseases
- InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
- InflaRx Hosts R&D Event Highlighting the Promise of INF904
- InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators
- InflaRx Reports First Quarter 2024 Financial Results and Provides Business Update
- InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024
- InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event
- InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans
- InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024
- InflaRx Appoints Jan Medina as Head of Investor Relations
